Cardiovascular Drugs

Cardiovascular Drugs

Cardiovascular Drugs market worldwide is projected to grow by US$7.8 Billion, driven by a compounded growth of 1.4%. Renin-Angiotensin System Blockers, one of the segments analyzed and sized in this study, displays the potential to grow at over 1.1%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$7.6 Billion by the year 2025, Renin-Angiotensin System Blockers will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 1.1% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$344.2 Million to the region's size and clout in the next 5 to 6 years. Over US$242.8 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Renin-Angiotensin System Blockers will reach a market size of US$174.8 Million by the close of the analysis period. As the world’s second largest economy and the new game changer in global markets, China exhibits the potential to grow at 1.9% over the next couple of years and add approximately US$1.9 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include among others, Abbott Laboratories, Inc.; Astellas Pharma US, Inc.; AstraZeneca PLC; Bayer AG; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche AG; Gilead Sciences, Inc.; Johnson & Johnson; Merck & Co., Inc.; Novartis International AG; Otsuka Pharmaceutical Co., Ltd.; Pfizer, Inc.; Sanofi-aventis U.S. LLC; Takeda Pharmaceutical Co., Ltd.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. INTRODUCTION, METHODOLOGY & REPORT SCOPE
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Global Competitor Market Shares
Cardiovascular Drugs Competitor Market Share Scenario Worldwide (in %): 2019 & 2028
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: Cardiovascular Drugs Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025
TABLE 2: Cardiovascular Drugs Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017
TABLE 3: Cardiovascular Drugs Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025
TABLE 4: Renin-Angiotensin System Blockers (Drug Class) World Market by Region/Country in US$ Million: 2018 to 2025
TABLE 5: Renin-Angiotensin System Blockers (Drug Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017
TABLE 6: Renin-Angiotensin System Blockers (Drug Class) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025
TABLE 7: Beta Blockers (Drug Class) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025
TABLE 8: Beta Blockers (Drug Class) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017
TABLE 9: Beta Blockers (Drug Class) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025
TABLE 10: Diuretics (Drug Class) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025
TABLE 11: Diuretics (Drug Class) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017
TABLE 12: Diuretics (Drug Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025
TABLE 13: Anti-Clotting Agents (Drug Class) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025
TABLE 14: Anti-Clotting Agents (Drug Class) Market Historic Review by Region/Country in US$ Million: 2009 to 2017
TABLE 15: Anti-Clotting Agents (Drug Class) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025
TABLE 16: Antihyperlipidemics (Drug Class) World Market by Region/Country in US$ Million: 2018 to 2025
TABLE 17: Antihyperlipidemics (Drug Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017
TABLE 18: Antihyperlipidemics (Drug Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025
TABLE 19: Other Drug Classes (Drug Class) World Market Estimates and Forecasts in US$ Million by Region/Country: 2018 to 2025
TABLE 20: Other Drug Classes (Drug Class) Market Worldwide Historic Review by Region/Country in US$ Million: 2009 to 2017
TABLE 21: Other Drug Classes (Drug Class) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025
TABLE 22: Hypertension (Indication) Market Opportunity Analysis Worldwide in US$ Million by Region/Country: 2018 to 2025
TABLE 23: Hypertension (Indication) Global Historic Demand in US$ Million by Region/Country: 2009 to 2017
TABLE 24: Hypertension (Indication) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025
TABLE 25: Hyperlipidemia (Indication) World Market by Region/Country in US$ Million: 2018 to 2025
TABLE 26: Hyperlipidemia (Indication) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017
TABLE 27: Hyperlipidemia (Indication) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025
TABLE 28: Coronary Artery Disease & Peripheral Artery Disease (Indication) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025
TABLE 29: Coronary Artery Disease & Peripheral Artery Disease (Indication) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017
TABLE 30: Coronary Artery Disease & Peripheral Artery Disease (Indication) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025
TABLE 31: Other Indications (Indication) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025
TABLE 32: Other Indications (Indication) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017
TABLE 33: Other Indications (Indication) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025
III. MARKET ANALYSIS
GEOGRAPHIC MARKET ANALYSIS
UNITED STATES
Market Facts & Figures
US Cardiovascular Drugs Market Share (in %) by Company: 2019 & 2025
TABLE 34: United States Cardiovascular Drugs Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025
TABLE 35: Cardiovascular Drugs Market in the United States by Drug Class: A Historic Review in US$ Million for 2009-2017
TABLE 36: United States Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
TABLE 37: United States Cardiovascular Drugs Market Estimates and Projections in US$ Million by Indication: 2018 to 2025
TABLE 38: Cardiovascular Drugs Market in the United States by Indication: A Historic Review in US$ Million for 2009-2017
TABLE 39: United States Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
CANADA
TABLE 40: Canadian Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025
TABLE 41: Canadian Cardiovascular Drugs Historic Market Review by Drug Class in US$ Million: 2009-2017
TABLE 42: Cardiovascular Drugs Market in Canada: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025
TABLE 43: Canadian Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018 to 2025
TABLE 44: Canadian Cardiovascular Drugs Historic Market Review by Indication in US$ Million: 2009-2017
TABLE 45: Cardiovascular Drugs Market in Canada: Percentage Share Breakdown of Sales by Indication for 2009, 2019, and 2025
JAPAN
TABLE 46: Japanese Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025
TABLE 47: Cardiovascular Drugs Market in Japan: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017
TABLE 48: Japanese Cardiovascular Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
TABLE 49: Japanese Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Indication for the Period 2018-2025
TABLE 50: Cardiovascular Drugs Market in Japan: Historic Sales Analysis in US$ Million by Indication for the Period 2009-2017
TABLE 51: Japanese Cardiovascular Drugs Market Share Analysis by Indication: 2009 VS 2019 VS 2025
CHINA
TABLE 52: Chinese Cardiovascular Drugs Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025
TABLE 53: Cardiovascular Drugs Historic Market Analysis in China in US$ Million by Drug Class: 2009-2017
TABLE 54: Chinese Cardiovascular Drugs Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
TABLE 55: Chinese Cardiovascular Drugs Market Growth Prospects in US$ Million by Indication for the Period 2018-2025
TABLE 56: Cardiovascular Drugs Historic Market Analysis in China in US$ Million by Indication: 2009-2017
TABLE 57: Chinese Cardiovascular Drugs Market by Indication: Percentage Breakdown of Sales for 2009, 2019, and 2025
EUROPE
Market Facts & Figures
European Cardiovascular Drugs Market: Competitor Market Share Scenario (in %) for 2019 & 2025
TABLE 58: European Cardiovascular Drugs Market Demand Scenario in US$ Million by Region/Country: 2018-2025
TABLE 59: Cardiovascular Drugs Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017
TABLE 60: European Cardiovascular Drugs Market Share Shift by Region/Country: 2009 VS 2019 VS 2025
TABLE 61: European Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025
TABLE 62: Cardiovascular Drugs Market in Europe in US$ Million by Drug Class: A Historic Review for the Period 2009-2017
TABLE 63: European Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
TABLE 64: European Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018-2025
TABLE 65: Cardiovascular Drugs Market in Europe in US$ Million by Indication: A Historic Review for the Period 2009-2017
TABLE 66: European Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
FRANCE
TABLE 67: Cardiovascular Drugs Market in France by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025
TABLE 68: French Cardiovascular Drugs Historic Market Scenario in US$ Million by Drug Class: 2009-2017
TABLE 69: French Cardiovascular Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
TABLE 70: Cardiovascular Drugs Market in France by Indication: Estimates and Projections in US$ Million for the Period 2018-2025
TABLE 71: French Cardiovascular Drugs Historic Market Scenario in US$ Million by Indication: 2009-2017
TABLE 72: French Cardiovascular Drugs Market Share Analysis by Indication: 2009 VS 2019 VS 2025
GERMANY
TABLE 73: Cardiovascular Drugs Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025
TABLE 74: German Cardiovascular Drugs Historic Market Analysis in US$ Million by Drug Class: 2009-2017
TABLE 75: German Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
TABLE 76: Cardiovascular Drugs Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Indication for the Period 2018-2025
TABLE 77: German Cardiovascular Drugs Historic Market Analysis in US$ Million by Indication: 2009-2017
TABLE 78: German Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
ITALY
TABLE 79: Italian Cardiovascular Drugs Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025
TABLE 80: Cardiovascular Drugs Historic Market Analysis in Italy in US$ Million by Drug Class: 2009-2017
TABLE 81: Italian Cardiovascular Drugs Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
TABLE 82: Italian Cardiovascular Drugs Market Growth Prospects in US$ Million by Indication for the Period 2018-2025
TABLE 83: Cardiovascular Drugs Historic Market Analysis in Italy in US$ Million by Indication: 2009-2017
TABLE 84: Italian Cardiovascular Drugs Market by Indication: Percentage Breakdown of Sales for 2009, 2019, and 2025
UNITED KINGDOM
TABLE 85: United Kingdom Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025
TABLE 86: Cardiovascular Drugs Market in the United Kingdom: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017
TABLE 87: United Kingdom Cardiovascular Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
TABLE 88: United Kingdom Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Indication for the Period 2018-2025
TABLE 89: Cardiovascular Drugs Market in the United Kingdom: Historic Sales Analysis in US$ Million by Indication for the Period 2009-2017
TABLE 90: United Kingdom Cardiovascular Drugs Market Share Analysis by Indication: 2009 VS 2019 VS 2025
SPAIN
TABLE 91: Spanish Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025
TABLE 92: Spanish Cardiovascular Drugs Historic Market Review by Drug Class in US$ Million: 2009-2017
TABLE 93: Cardiovascular Drugs Market in Spain: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025
TABLE 94: Spanish Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018 to 2025
TABLE 95: Spanish Cardiovascular Drugs Historic Market Review by Indication in US$ Million: 2009-2017
TABLE 96: Cardiovascular Drugs Market in Spain: Percentage Share Breakdown of Sales by Indication for 2009, 2019, and 2025
RUSSIA
TABLE 97: Russian Cardiovascular Drugs Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025
TABLE 98: Cardiovascular Drugs Market in Russia by Drug Class: A Historic Review in US$ Million for 2009-2017
TABLE 99: Russian Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
TABLE 100: Russian Cardiovascular Drugs Market Estimates and Projections in US$ Million by Indication: 2018 to 2025
TABLE 101: Cardiovascular Drugs Market in Russia by Indication: A Historic Review in US$ Million for 2009-2017
TABLE 102: Russian Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
REST OF EUROPE
TABLE 103: Rest of Europe Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025
TABLE 104: Cardiovascular Drugs Market in Rest of Europe in US$ Million by Drug Class: A Historic Review for the Period 2009-2017
TABLE 105: Rest of Europe Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
TABLE 106: Rest of Europe Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018-2025
TABLE 107: Cardiovascular Drugs Market in Rest of Europe in US$ Million by Indication: A Historic Review for the Period 2009-2017
TABLE 108: Rest of Europe Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
ASIA-PACIFIC
TABLE 109: Asia-Pacific Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025
TABLE 110: Cardiovascular Drugs Market in Asia-Pacific: Historic Market Analysis in US$ Million by Region/Country for the Period 2009-2017
TABLE 111: Asia-Pacific Cardiovascular Drugs Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025
TABLE 112: Cardiovascular Drugs Market in Asia-Pacific by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025
TABLE 113: Asia-Pacific Cardiovascular Drugs Historic Market Scenario in US$ Million by Drug Class: 2009-2017
TABLE 114: Asia-Pacific Cardiovascular Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
TABLE 115: Cardiovascular Drugs Market in Asia-Pacific by Indication: Estimates and Projections in US$ Million for the Period 2018-2025
TABLE 116: Asia-Pacific Cardiovascular Drugs Historic Market Scenario in US$ Million by Indication: 2009-2017
TABLE 117: Asia-Pacific Cardiovascular Drugs Market Share Analysis by Indication: 2009 VS 2019 VS 2025
AUSTRALIA
TABLE 118: Cardiovascular Drugs Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025
TABLE 119: Australian Cardiovascular Drugs Historic Market Analysis in US$ Million by Drug Class: 2009-2017
TABLE 120: Australian Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
TABLE 121: Cardiovascular Drugs Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Indication for the Period 2018-2025
TABLE 122: Australian Cardiovascular Drugs Historic Market Analysis in US$ Million by Indication: 2009-2017
TABLE 123: Australian Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
INDIA
TABLE 124: Indian Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025
TABLE 125: Indian Cardiovascular Drugs Historic Market Review by Drug Class in US$ Million: 2009-2017
TABLE 126: Cardiovascular Drugs Market in India: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025
TABLE 127: Indian Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018 to 2025
TABLE 128: Indian Cardiovascular Drugs Historic Market Review by Indication in US$ Million: 2009-2017
TABLE 129: Cardiovascular Drugs Market in India: Percentage Share Breakdown of Sales by Indication for 2009, 2019, and 2025
SOUTH KOREA
TABLE 130: Cardiovascular Drugs Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025
TABLE 131: South Korean Cardiovascular Drugs Historic Market Analysis in US$ Million by Drug Class: 2009-2017
TABLE 132: Cardiovascular Drugs Market Share Distribution in South Korea by Drug Class: 2009 VS 2019 VS 2025
TABLE 133: Cardiovascular Drugs Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Indication for the Period 2018-2025
TABLE 134: South Korean Cardiovascular Drugs Historic Market Analysis in US$ Million by Indication: 2009-2017
TABLE 135: Cardiovascular Drugs Market Share Distribution in South Korea by Indication: 2009 VS 2019 VS 2025
REST OF ASIA-PACIFIC
TABLE 136: Rest of Asia-Pacific Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025
TABLE 137: Cardiovascular Drugs Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017
TABLE 138: Rest of Asia-Pacific Cardiovascular Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
TABLE 139: Rest of Asia-Pacific Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Indication for the Period 2018-2025
TABLE 140: Cardiovascular Drugs Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Indication for the Period 2009-2017
TABLE 141: Rest of Asia-Pacific Cardiovascular Drugs Market Share Analysis by Indication: 2009 VS 2019 VS 2025
LATIN AMERICA
TABLE 142: Latin American Cardiovascular Drugs Market Trends by Region/Country in US$ Million: 2018-2025
TABLE 143: Cardiovascular Drugs Market in Latin America in US$ Million by Region/Country: A Historic Perspective for the Period 2009-2017
TABLE 144: Latin American Cardiovascular Drugs Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025
TABLE 145: Latin American Cardiovascular Drugs Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025
TABLE 146: Cardiovascular Drugs Historic Market Analysis in Latin America in US$ Million by Drug Class: 2009-2017
TABLE 147: Latin American Cardiovascular Drugs Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
TABLE 148: Latin American Cardiovascular Drugs Market Growth Prospects in US$ Million by Indication for the Period 2018-2025
TABLE 149: Cardiovascular Drugs Historic Market Analysis in Latin America in US$ Million by Indication: 2009-2017
TABLE 150: Latin American Cardiovascular Drugs Market by Indication: Percentage Breakdown of Sales for 2009, 2019, and 2025
ARGENTINA
TABLE 151: Argentinean Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025
TABLE 152: Cardiovascular Drugs Market in Argentina in US$ Million by Drug Class: A Historic Review for the Period 2009-2017
TABLE 153: Argentinean Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
TABLE 154: Argentinean Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018-2025
TABLE 155: Cardiovascular Drugs Market in Argentina in US$ Million by Indication: A Historic Review for the Period 2009-2017
TABLE 156: Argentinean Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
BRAZIL
TABLE 157: Cardiovascular Drugs Market in Brazil by Drug Class: Estimates and Projections in US$ Million for the Period 2018-2025
TABLE 158: Brazilian Cardiovascular Drugs Historic Market Scenario in US$ Million by Drug Class: 2009-2017
TABLE 159: Brazilian Cardiovascular Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
TABLE 160: Cardiovascular Drugs Market in Brazil by Indication: Estimates and Projections in US$ Million for the Period 2018-2025
TABLE 161: Brazilian Cardiovascular Drugs Historic Market Scenario in US$ Million by Indication: 2009-2017
TABLE 162: Brazilian Cardiovascular Drugs Market Share Analysis by Indication: 2009 VS 2019 VS 2025
MEXICO
TABLE 163: Cardiovascular Drugs Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025
TABLE 164: Mexican Cardiovascular Drugs Historic Market Analysis in US$ Million by Drug Class: 2009-2017
TABLE 165: Mexican Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
TABLE 166: Cardiovascular Drugs Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Indication for the Period 2018-2025
TABLE 167: Mexican Cardiovascular Drugs Historic Market Analysis in US$ Million by Indication: 2009-2017
TABLE 168: Mexican Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
REST OF LATIN AMERICA
TABLE 169: Rest of Latin America Cardiovascular Drugs Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025
TABLE 170: Cardiovascular Drugs Market in Rest of Latin America by Drug Class: A Historic Review in US$ Million for 2009-2017
TABLE 171: Rest of Latin America Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
TABLE 172: Rest of Latin America Cardiovascular Drugs Market Estimates and Projections in US$ Million by Indication: 2018 to 2025
TABLE 173: Cardiovascular Drugs Market in Rest of Latin America by Indication: A Historic Review in US$ Million for 2009-2017
TABLE 174: Rest of Latin America Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
MIDDLE EAST
TABLE 175: The Middle East Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025
TABLE 176: Cardiovascular Drugs Market in the Middle East by Region/Country in US$ Million: 2009-2017
TABLE 177: The Middle East Cardiovascular Drugs Market Share Breakdown by Region/Country: 2009, 2019, and 2025
TABLE 178: The Middle East Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018 to 2025
TABLE 179: The Middle East Cardiovascular Drugs Historic Market by Drug Class in US$ Million: 2009-2017
TABLE 180: Cardiovascular Drugs Market in the Middle East: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025
TABLE 181: The Middle East Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018 to 2025
TABLE 182: The Middle East Cardiovascular Drugs Historic Market by Indication in US$ Million: 2009-2017
TABLE 183: Cardiovascular Drugs Market in the Middle East: Percentage Share Breakdown of Sales by Indication for 2009, 2019, and 2025
IRAN
TABLE 184: Iranian Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Drug Class for the Period 2018-2025
TABLE 185: Cardiovascular Drugs Market in Iran: Historic Sales Analysis in US$ Million by Drug Class for the Period 2009-2017
TABLE 186: Iranian Cardiovascular Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025
TABLE 187: Iranian Market for Cardiovascular Drugs: Annual Sales Estimates and Projections in US$ Million by Indication for the Period 2018-2025
TABLE 188: Cardiovascular Drugs Market in Iran: Historic Sales Analysis in US$ Million by Indication for the Period 2009-2017
TABLE 189: Iranian Cardiovascular Drugs Market Share Analysis by Indication: 2009 VS 2019 VS 2025
ISRAEL
TABLE 190: Israeli Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Drug Class: 2018-2025
TABLE 191: Cardiovascular Drugs Market in Israel in US$ Million by Drug Class: A Historic Review for the Period 2009-2017
TABLE 192: Israeli Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
TABLE 193: Israeli Cardiovascular Drugs Market Estimates and Forecasts in US$ Million by Indication: 2018-2025
TABLE 194: Cardiovascular Drugs Market in Israel in US$ Million by Indication: A Historic Review for the Period 2009-2017
TABLE 195: Israeli Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
SAUDI ARABIA
TABLE 196: Saudi Arabian Cardiovascular Drugs Market Growth Prospects in US$ Million by Drug Class for the Period 2018-2025
TABLE 197: Cardiovascular Drugs Historic Market Analysis in Saudi Arabia in US$ Million by Drug Class: 2009-2017
TABLE 198: Saudi Arabian Cardiovascular Drugs Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
TABLE 199: Saudi Arabian Cardiovascular Drugs Market Growth Prospects in US$ Million by Indication for the Period 2018-2025
TABLE 200: Cardiovascular Drugs Historic Market Analysis in Saudi Arabia in US$ Million by Indication: 2009-2017
TABLE 201: Saudi Arabian Cardiovascular Drugs Market by Indication: Percentage Breakdown of Sales for 2009, 2019, and 2025
UNITED ARAB EMIRATES
TABLE 202: Cardiovascular Drugs Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025
TABLE 203: United Arab Emirates Cardiovascular Drugs Historic Market Analysis in US$ Million by Drug Class: 2009-2017
TABLE 204: Cardiovascular Drugs Market Share Distribution in United Arab Emirates by Drug Class: 2009 VS 2019 VS 2025
TABLE 205: Cardiovascular Drugs Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Indication for the Period 2018-2025
TABLE 206: United Arab Emirates Cardiovascular Drugs Historic Market Analysis in US$ Million by Indication: 2009-2017
TABLE 207: Cardiovascular Drugs Market Share Distribution in United Arab Emirates by Indication: 2009 VS 2019 VS 2025
REST OF MIDDLE EAST
TABLE 208: Cardiovascular Drugs Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Drug Class for the Period 2018-2025
TABLE 209: Rest of Middle East Cardiovascular Drugs Historic Market Analysis in US$ Million by Drug Class: 2009-2017
TABLE 210: Rest of Middle East Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
TABLE 211: Cardiovascular Drugs Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Indication for the Period 2018-2025
TABLE 212: Rest of Middle East Cardiovascular Drugs Historic Market Analysis in US$ Million by Indication: 2009-2017
TABLE 213: Rest of Middle East Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
AFRICA
TABLE 214: African Cardiovascular Drugs Market Estimates and Projections in US$ Million by Drug Class: 2018 to 2025
TABLE 215: Cardiovascular Drugs Market in Africa by Drug Class: A Historic Review in US$ Million for 2009-2017
TABLE 216: African Cardiovascular Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025
TABLE 217: African Cardiovascular Drugs Market Estimates and Projections in US$ Million by Indication: 2018 to 2025
TABLE 218: Cardiovascular Drugs Market in Africa by Indication: A Historic Review in US$ Million for 2009-2017
TABLE 219: African Cardiovascular Drugs Market Share Breakdown by Indication: 2009 VS 2019 VS 2025
IV. COMPETITION
ABBOTT LABORATORIES
ASTELLAS PHARMA US
ASTRAZENECA PLC
BAYER AG
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL-MYERS SQUIBB COMPANY
ELI LILLY AND COMPANY
F. HOFFMANN-LA ROCHE AG
GILEAD SCIENCES
JOHNSON & JOHNSON
MERCK & CO., INC.
NOVARTIS INTERNATIONAL AG
OTSUKA PHARMACEUTICAL
PFIZER
SANOFI-AVENTIS US
TAKEDA PHARMACEUTICAL COMPANY LIMITED
V. CURATED RESEARCH

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook